Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2026-06-05 17:20:18 ET · period of report 2026-06-03 · accession 0001721020-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-05 17:20 | 2026-06-03 | KROS | Seth Alpna | Dir | A - Grant | $0.00 | +7,142 | 12.4K | +136% | $0 |
| D | 2026-06-05 17:20 | 2026-06-03 | KROS | Seth Alpna | Dir | A - Grant | $0.00 | +7,433 | 7,433 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-03 | A | A | 7,142 | $0.00 | 12,392 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. |
| 2 | Derivative | Stock Option (right to buy) | 2026-06-03 | A | A | 7,433 | $0.00 | 7,433 | D | $10.50 · — to 2036-06-02 | 7,433 Common Stock | (F2) The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. |